Back to Search
Start Over
Factors Associated With an Electronic Health Record-Based Definition of Postacute Sequelae of COVID-19 in Patients With Systemic Autoimmune Rheumatic Disease.
- Source :
-
The Journal of rheumatology [J Rheumatol] 2024 May 01; Vol. 51 (5), pp. 529-537. Date of Electronic Publication: 2024 May 01. - Publication Year :
- 2024
-
Abstract
- Objective: Many individuals with rheumatic disease are at higher risk for severe acute coronavirus disease 2019 (COVID-19). We aimed to evaluate risk factors for postacute sequelae of COVID-19 (PASC) using an electronic health record (EHR)-based definition.<br />Methods: We identified patients with prevalent rheumatic diseases and COVID-19 within the Mass General Brigham healthcare system. PASC was defined by the International Classification of Diseases, 10th revision (ICD-10) codes, relevant labs, vital signs, and medications at least 30 days following the first COVID-19 infection. Patients were followed until the earliest of incident PASC, repeat COVID-19 infection, 1 year of follow-up, death, or February 19, 2023. We used multivariable Cox regression to estimate the association of baseline characteristics with PASC risk.<br />Results: Among 2459 patients (76.37% female, mean age 57.4 years), the most common incident PASC manifestations were cough (14.56%), dyspnea (12.36%), constipation (11.39%), and fatigue (10.70%). Serious manifestations including acute coronary disease (4.43%), thromboembolism (3.09%), hypoxemia (3.09%), stroke (1.75%), and myocarditis (0.12%) were rare. The Delta wave (adjusted hazard ratio [aHR] 0.63, 95% CI 0.49-0.82) and Omicron era (aHR 0.50, 95% CI 0.41-0.62) were associated with lower risk of PASC than the early pandemic period (March 2020-June 2021). Age, obesity, comorbidity burden, race, and hospitalization for acute COVID-19 infection were associated with greater risk of PASC. Glucocorticoid (GC) use (aHR 1.19, 95% CI 1.05-1.34 compared to no use) was associated with greater risk of PASC.<br />Conclusion: Among patients with rheumatic diseases, following their first COVID-19 infection, we found a decreased risk of PASC over calendar time using an EHR-based definition. Aside from GCs, no specific immunomodulatory medications were associated with increased risk, and risk factors were otherwise similar to those seen in the general population.<br /> (Copyright © 2024 by the Journal of Rheumatology.)
- Subjects :
- Humans
Female
Male
Middle Aged
Aged
Risk Factors
SARS-CoV-2
Adult
Autoimmune Diseases epidemiology
Autoimmune Diseases complications
Post-Acute COVID-19 Syndrome
Comorbidity
COVID-19 epidemiology
COVID-19 complications
Electronic Health Records
Rheumatic Diseases epidemiology
Rheumatic Diseases complications
Subjects
Details
- Language :
- English
- ISSN :
- 1499-2752
- Volume :
- 51
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- The Journal of rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 38428964
- Full Text :
- https://doi.org/10.3899/jrheum.2023-1092